SNOW earnings call for the period ending December 31, 2020.
Plus, how to get an additional discount.
The "Sourcing Software Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeNucleus Financial Group PLC(c) Name of the party to the offer with which exempt principal trader is connected:Nucleus Financial Group PLC(d) Date dealing undertaken:13 April 2021(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?No 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (a) Purchases and sales Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/receivedOrdinaryPurchases6,687185p185p (b) Derivatives transactions (other than options) Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) Exercising Class of relevant securityProduct descriptione.g. call optionNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable) The currency of all prices and other monetary amounts should be stated. Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. 3. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:If there are no such agreements, arrangements or understandings, state “none” None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” None Date of disclosure:14/04/2021Contact name:Molly AdkinTelephone number:020 7647 8154 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at email@example.com. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
The country music singer-songwriter was suspended indefinitely from his label in February.
Following rare blood clots, the US, South Africa and EU have suspended the jab.
Forecasts by Manufacturing Type (Outsourced, In-house), by Expression Platform (Mammalian Cell Cultures, Microbial Fermentations, Others), by Application (Vaccines, MABs, Insulin Analogues, Interferon Therapies, Human Growth Hormones, Other Therapeutic Areas) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Biological Drug API Manufacturing Companies AND COVID-19 Recovery Scenarios.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biological Drug API Manufacturing Services Market Report 2021-2031" - https://www.reportlinker.com/p06058469/?utm_source=GNW Biological Drug API Manufacturing Services Set to Witness Significant Growth Over Next 10 Years The opportunity to become a market leader in the rapidly growing biosimilar industry has spurred many companies to invest in biosimilar development, either directly or through a partnership with a more experienced CMO. Currently, in 2020, there are over 55 approved biosimilars in the EU and the market for these products is expected to grow rapidly in the coming 10 years. Demand for lower-cost biological therapies in developed and emerging markets, as well as patent expires for blockbuster biologics, will drive investment in biosimilar development. CMOs that can offer expertise and biomanufacturing capacity will benefit from contracts with biosimilar developers, such as small molecule generic drug manufacturers, as well as emerging biosimilar manufacturers looking to launch their follow-on biologics in developed markets. U.S. Holds the Maximum Market Share in Global Biological Drug API Manufacturing Services Market The US is the global leader of the biological drug API manufacturing service market and this is no surprise as it also has the highest level of demand worldwide for pharmaceuticals, including outsourced API manufacturing. Per person, the US spends around one thousand dollars a year on pharmaceuticals, higher than any other country in the world. Additionally, pharmaceuticals cost more in the US, with some drugs being twice the price they are in the UK and Canada. This is because the US government does not regulate its pharma prices. Furthermore, the opaque US health system makes it hard to draw drug-by-drug comparisons with prices abroad. The majority of the leading biotech CMOs have facilities in the United States, which provide APIs domestically. In 2020, US market accounted for US$ xx million, or over 90%, of the North American biological drug API manufacturing services revenues. Emerging markets are no longer as cheap as they used to be and additionally, emerging markets do not always meet quality standards. This deficiency in standards and rise in costs because of the demands for compliance to standards has increased the demand in the US market. Local manufacturers can also provide products more conveniently, as there are less communication or timing issues. Discover how to stay ahead Our 350+ page report provides 350+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biological Drug API Manufacturing Services Market. See how to exploit the opportunities. Forecasts to 2031 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), SWOT Analysis, product profiles and commercial developments. Discover sales predictions for the world market and sub-markets. By Manufacturing Type • Outsourced • In-house By Expression Platform • Mammalian Cell Cultures • Microbial Fermentations • Others By Application • Vaccines • MABs • Insulin Analogues • Interferon Therapies • Human Growth Hormones • Other Therapeutic Areas In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 22 leading national markets: By Region • North America – U.S. – Canada • Europe – Germany – France – UK – Italy – Spain – Russia – Switzerland – Netherlands – Rest of Europe • Asia Pacific – China – Japan – India – Australia – South Korea – Singapore – Rest of Asia Pacific • Latin America – Brazil – Mexico – Colombia – Argentina – Rest of Latin America • Middle East & Africa – GCC – South Africa – Rest of Middle East & Africa Leading companies and the potential for market growth Overall world revenue for Biological Drug API Manufacturing Services Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Biological Drug API Manufacturing Services Market report helps you In summary, our 350+ page report provides you with the following knowledge: • Revenue forecasts to 2031 for Biological Drug API Manufacturing Services Market, with forecasts for Manufacturing Type, Expression Platform, and Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2031 for 5 regional and 22 key national markets– See forecasts for the Biological Drug API Manufacturing Services market in North America, Europe, Asia Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, Singapore, among other prominent economies. • Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Biological Drug API Manufacturing Services Market. Some of the company’s profiled in this report include Bristol-Myers Squibb Co., Samsung Biologics, AbbVie, GSK Biopharmaceuticals, Lonza Group Ltd., NEKTAR THERAPEUTICS, Boehringer, Patheon N.V., Cytovance Biologics, and Fujifilm Diosynth Biotechnologies. Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Biological Drug API Manufacturing Services Market and leading companies. You will find data, trends, and predictions.Read the full report: https://www.reportlinker.com/p06058469/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
People returning from holidays in ‘green’ countries will not be required to self-isolate under the new traffic light system.
Another Round, nominated in Best International Feature Film and Best Director categories at the #Oscars2021, revolves around four weary high school teachers experimenting with the liberating effects of alcohol.
Toshiba's board planned to oust troubled CEO Nobuaki Kurumatani before CVC Capital Partners launched a $20 billion buyout bid last week, informing him a day before the offer was announced that it would replace him, people familiar with the matter said. Two members of Toshiba Corp's nomination committee, including board chairman Osamu Nagayama, met Kurumatani, himself a former CVC executive, and told him they intended to look for a new chief executive, three of the people said. Kurumatani then told them of the European private equity firm's plan to take Toshiba private, the three people said.
The "Drafting Commercial Contracts Training Course" training has been added to ResearchAndMarkets.com's offering.
Dublin, April 14, 2021 (GLOBE NEWSWIRE) -- The "Global Fructose Market By Product (High Fructose Corn Syrup, Fructose Syrups and Fructose Solids), By Application (Beverage, Processed Foods, Dairy Products, Bakery & Cereals, Confectionary and Other Applications), By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The Global Fructose Market size is expected to reach $6.1 billion by 2026, rising at a market growth of 8.2% CAGR during the forecast period. Fructose is a form of sweetener which is primarily utilized in the food and beverage sector. The clearest form of fructose is acquired with the help of corn or sugar processing and it is extensively utilized in the food & beverages industry. Fructose has been an important aspect of the processed food industry since the last decade.In comparison to other external sweeteners, fructose is less harmful and has encouraged as a non-caloric rising substance. Among different forms of the fructose available in the market one is the clear form fructose, generally called crystalline fructose and the other form is a blend of fructose and glucose and sold as high fructose corn syrup. The purest form of fructose is extensively utilized in baked items as it enhances its texture, quality and adds aroma to it.Increasing demand for low-sugar, low-fat, and processed low-calorie food items is anticipated to boost the growth of the industry. Fructose is a monosaccharide with a chemical formula like that of glucose but a dissimilar molecular structure. Fruits, vegetables, honey, and some plants contain fructose naturally. Fructose is utilized in food & beverages for improving their quality, taste, and texture. Moreover, the low Glycemic Index (GI) attached with the product in comparison to table sugar will probably boost its demand.By ProductBased on Product, the market is segmented into High Fructose Corn Syrup, Fructose Syrups and Fructose Solids. In 2019, the market was dominated by High fructose corn syrup with a major revenue share. These products are increasingly gaining traction due to their versatility and capacity to improve the texture, color, quality, and flavor of several foods and beverages. Besides, manufacturing companies consider high fructose corn syrup due to its liquid state, which offers an easy production process and lower costs compared to other calorie sweeteners. For example, the utilization of sugar rather than high fructose corn syrup in soft drinks expands the sweetener cost two times.By ApplicationBased on Application, the market is segmented into Beverage, Processed Foods, Dairy Products, Bakery & Cereals, Confectionary and Other Applications. The food processing application segment is expected to witness the highest CAGR during the forecast period. This is credited to the increasing technological developments and innovations coupled with the massive demand for processed food products. The increasing acceptance of packaged meals, snacks, and desserts is anticipated to fuel the fructose demand in food and beverage applications.By RegionBased on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The global fructose market was dominated by North America with a considerable revenue share in 2019. The rising acceptance of packaged beverages in the region like juices, sports drinks, and carbonated soft drinks, has encouraged the growth of the industry. On the other hand, consumers in the region are slowly shifting their focus towards organic items, which is likely to influence the product demand adversely.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Archer Daniels Midland Company, Cargill Corporation, DuPont de Nemours, Inc., Ingredion, Incorporated, Tate & Lyle PLC, Shijazhuang Huaxu Pharmaceuticals Co. Ltd., Dulcette Technologies LLC (Viachem, Inc.), Bell Chem Corp., Atlantic Chemicals Trading GmbH, and Galam Ltd.Unique Offerings from the Publisher Exhaustive coverageHighest number of market tables and figuresSubscription based model availableGuaranteed best priceAssured post sales research support with 10% customization free Key Topics Covered: Chapter 1. Market Scope & Methodology1.1 Market Definition1.2 Objectives1.3 Market Scope1.4 Segmentation1.4.1 Global Fructose Market, by Product1.4.2 Global Fructose Market, by Application1.4.3 Global Fructose Market, by Geography1.5 Methodology for the researchChapter 2. Market Overview2.1 Introduction2.1.1 Overview2.1.2 Market Composition2.2 Key Factors Impacting the Market2.2.1 Market Drivers2.2.2 Market RestraintsChapter 3. Recent Developments in Global Fructose MarketChapter 4. Global Fructose Market by Product4.1 Global High Fructose Corn Syrup Market by Region4.2 Global Fructose Syrups Market by Region4.3 Global Fructose Solids Market by RegionChapter 5. Global Fructose Market by Application5.1 Global Beverage Market by Region5.2 Global Processed Foods Market by Region5.3 Global Dairy Products Market by Region5.4 Global Bakery & Cereals Market by Region5.5 Global Confectionary Market by Region5.6 Global Other Application Market by RegionChapter 6. Global Fructose Market by Region6.1 North America Fructose Market6.2 North America Fructose Market by Application6.3 North America Fructose Market by Country6.4 Canada Fructose Market6.5 Mexico Fructose Market6.6 Rest of North America Fructose Market6.7 Europe Fructose Market6.8 Asia Pacific Fructose MarketChapter 7. Company Profiles7.1 Archer Daniels Midland Company7.1.1 Company Overview7.1.2 Financial Analysis7.1.3 Segmental and Regional Analysis7.1.4 Research & Development Expense7.1.5 Recent strategies and developments:18.104.22.168 Geographical Expansions:22.214.171.124 Partnerships, Collaborations, and Agreements:7.2 Cargill Corporation7.2.1 Company Overview7.2.2 Financial Analysis7.2.3 Regional Analysis7.2.1 Recent strategies and developments:126.96.36.199 Product Launches and Product Expansions:188.8.131.52 Geographical Expansions:7.3 DuPont de Nemours, Inc.7.3.1 Company Overview7.3.2 Financial Analysis7.3.3 Segmental and Regional Analysis7.3.4 Research & Development Expense7.4 Ingredion, Incorporated7.4.1 Company Overview7.4.2 Financial Analysis7.4.3 Regional Analysis7.4.4 Research & Development Expense7.4.5 Recent strategies and developments:184.108.40.206 Acquisition and Mergers:7.5 Tate & Lyle PLC7.5.1 Company Overview7.5.2 Financial Analysis7.5.3 Segmental Analysis7.5.4 Research & Development Expense7.5.5 Recent strategies and developments:220.127.116.11 Acquisition and Mergers:18.104.22.168 Product Launches and Product Expansions:7.6 Shijazhuang Huaxu Pharmaceuticals Co. Ltd.7.6.1 Company Overview7.7 Dulcette Technologies LLC (Viachem, Inc.)7.7.1 Company Overview7.8 Bell Chem Corp.7.8.1 Company Overview7.9 Atlantic Chemicals Trading GmbH7.9.1 Company Overview7.10. Galam Ltd.7.10.1 Company Overview7.10.2 Recent strategies and developments:22.214.171.124 Product Launches and Product Expansions: For more information about this report visit https://www.researchandmarkets.com/r/6ac1zv CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
LONDON — Queen Elizabeth II has returned to royal duties, four days after the death of her husband, Prince Philip. The 94-year-old British monarch attended a retirement ceremony for a senior royal official on Tuesday, according to the Court Circular, the official record of royal engagements. The royal family is observing two weeks of mourning for Philip, who died Friday at the age of 99. The palace has said members of the royal family will “undertake engagements appropriate to the circumstances” during the mourning period. The queen attended a ceremony at Windsor Castle for Lord Chamberlain Earl Peel, who has retired as the royal household’s most senior official. He oversaw arrangements for the funeral of Prince Philip, also known as the Duke of Edinburgh, until handing over to his successor days before the duke’s death. Philip’s funeral will take place Saturday at Windsor Castle, with attendance limited to 30 because of coronavirus restrictions. Servicemen and women from the Royal Navy, Royal Marines, Army and Royal Air Force will take part in the funeral procession, and Philip’s coffin will be borne to St. George’s Chapel at the castle on a specially adapted Land Rover, which he designed himself. The Associated Press
Euro zone citizens expect the European Central Bank's proposed digital euro to be private, safe and cheap, an ECB survey showed on Wednesday. The ECB is working on creating an electronic form of cash to complement banknotes and coins in a bid to stem competition from cryptocurrencies such as Bitcoin, Tether and Facebook’s proposed Diem. An ECB poll showed that privacy when making payments, a key feature of cash that some fear will get lost when switching to an electronic means of payment, was the number one priority for both private individuals and professionals.
LVMH's shares rose to record highs on Wednesday after the world's biggest luxury goods company posted sales figures that showed it had bounced back far more quickly than expected in early 2021. LVMH shares were up by 2.7% in early session trading, hitting new record levels, and also lifting up the shares of rival luxury goods companies such as Kering and Hermes. Late on Tuesday, LVMH posted first-quarter revenues that even exceeded 2019 levels, before the pandemic.
US political developments, as they happen
The 19-year-old looked set to leave the club when his current contract expires this summer
Airline says it is ready to scale operations according to demand, although it expects steep losses.
All the contenders to be the mystery relative
Israel marked its national Memorial Day for fallen soldiers on Wednesday, in a year when national attention has been focused on the plight of veterans suffering from psychological trauma. Memorial Day is the most solemn day on Israel's national calendar. Israel has fought half a dozen wars with neighboring Arab countries, battled two Palestinian uprisings and endured scores of deadly militant attacks since its establishment in 1948.
Forecasts by Service (Process Development (Downstream, Upstream), Fill & Finish Operations, Analytical & Quality Control Studies, Packaging), by Product (Biologics (Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Insulin), Biosimilars) Plus Analysis of Leading Companies.New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biopharmaceuticals Contract Manufacturing Market Report 2020-2030" - https://www.reportlinker.com/p06058471/?utm_source=GNW Market Dynamics • Continuing expansion of biopharmaceutical manufacturing capacity by CDMOs/CMOs • Increasing outsourcing of biopharmaceuticals-related manufacturing activities • Increasing demand for fill-finish services in biopharmaceutical contract manufacturing market • Increasing productivity and efficiency of biopharmaceuticals manufacturing processes • Uptake of single-use production systems by the biopharmaceutical manufacturing industry • Asia emerging as hot destination for biopharmaceutical manufacturing • Increasing confidence of pharmaceutical industry in CDMOs capabilities • High level of outsourcing of manufacturing newly approved drugs by smaller biotech companies is fueling the growth of biopharma-specific CMOs/CDMOs • Higher acceptance and success of biopharmaceutical products in the market provides tremendous opportunities to biopharmaceuticals contract manufacturers • Increasing shortage of skilled workforce in the biopharmaceutical industry • Expensive manufacturing equipment requirements and complex processes raise barriers to entry, which is limiting market growth • Complicated and stringent regulatory requirements hinder market growth Market Segmentation 2020-2030 Biopharmaceuticals Contract Manufacturing Market is segmented on the Service, Product, and Regional basis. Service • Process Development – Downstream – Upstream • Fill & Finish Operations • Analytical & Quality Control Studies • Packaging Product • Biologics – Monoclonal Antibodies (MAbs) – Recombinant Proteins – Vaccines – Insulin • Biosimilars Regional Breakdown Focused regional forecasts and analysis explore the future opportunities: • North America – U.S. – Canada • Europe – UK – France – Germany – Russia – Rest of Europe • Asia-Pacific – China – Japan – India – Southeast Asia – Rest of Asia Pacific • Latin America – Brazil – Argentina – Rest of Latin America • Middle East & Africa – GCC – South Africa – Rest of Middle EastRead the full report: https://www.reportlinker.com/p06058471/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001